TECHNIVIE Drug Patent Profile

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has four hundred and forty-eight patent family members in forty-seven countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Technivie

Technivie was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TECHNIVIE

International Patents:	448
US Patents:	8
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TECHNIVIE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE
DailyMed Link:	TECHNIVIE at DailyMed

See drug prices for TECHNIVIE

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for TECHNIVIE

NDA:

207931

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TECHNIVIE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 3
AbbVie	Phase 2

See all TECHNIVIE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TECHNIVIE

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for TECHNIVIE

TECHNIVIE is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y

Expired US Patents for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015

EU/EMA Drug Approvals for TECHNIVIE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Viekirax	ombitasvir, paritaprevir, ritonavir	EMEA/H/C/003839 Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults., , For hepatitis C virus (HCV) genotype specific activity.,	Authorised	no	no	no	2015-01-14

International Patents for TECHNIVIE

When does loss-of-exclusivity occur for TECHNIVIE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TECHNIVIE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6743135
Ecuador	SP17064986	COMPUESTOS ANTIVIRALES
European Patent Office	3344642	DÉRIVÉS ANTI-VIRAUX DE TÉTRAHYDROFURANE (ANTI-VIRAL TETRAHYDROFURANE DERIVATIVES)
Eurasian Patent Organization	201291394	ТВЕРДЫЕ КОМПОЗИЦИИ
Lithuania	PA2017033
Ecuador	SP13010937	COMPUESTOS ANTIVIRALES
Slovenia	2468286

Supplementary Protection Certificates for TECHNIVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2692346	PA2017033	Lithuania		PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2692346	1790050-7/1791051-4	Sweden		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.
2692346	PA2017033,C2692346	Lithuania		PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2340029	15C0021	France		PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
2340029	304 50009-2015	Slovakia		PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
2340029	122015000042	Germany		PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
2340029	599	Finland